Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
12 min read
Rhizomelic Chondrodysplasia Punctata, Type 3 Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Rhizomelic Chondrodysplasia in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Fingerprints, Absence Of Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Fingerprints, Absence Of in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Red-Cell Aplasia, Pure Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Red-Cell Aplasia, Pure in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Acth-Independent Macronodular Adrenal Hyperplasia Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Acth-Independent Macronodular in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Anti-Neutrophil Cytoplasmic in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Dystonia Musculorum Deformans Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Dystonia Musculorum Deformans in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap.
Latest Hotspot
12 min read
Agammaglobulinemia Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Agammaglobulinemia with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Arthrogryposis Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Arthrogryposis with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Inosine Triphosphatase Deficiency Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Inosine Triphosphatase in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Duane Retraction Syndrome Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Duane Retraction Syndrome in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Ectodermal Dysplasia Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Ectodermal Dysplasia with 2026 evidence on epidemiology, target biology, clinical competition, unmet need, deals and market attractiveness via Patsnap MCP..
Latest Hotspot
12 min read
Idiopathic Inflammatory Myopathies Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook
18 August 2026
Evaluate Idiopathic Inflammatory in 2026: epidemiology, target biology, clinical competition, unmet need, deal activity and market attractiveness via Patsnap MCP..